Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of TPST‐1120 in advance Cancer

Trial Profile

A clinical study of TPST‐1120 in advance Cancer

Phase of Trial: Phase I

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs TPST-1120 (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Dec 2018 New trial record
    • 13 Nov 2018 According to a Tempest Therapeutics media release, the company expects to start this study in early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top